Abstract
The bacterial capsule is a recognized virulence factor in pathogenic bacteria. It likely works as an antiphagocytic barrier by minimizing complement deposition on the bacterial surface. With the continual rise of bacterial pathogens resistant to multiple antibiotics, there is an increasing need for novel drugs. In the Wzy-dependent pathway, the biosynthesis of capsular polysaccharide (CPS) is regulated by a phosphoregulatory system, whose main components consist of bacterial-tyrosine kinases (BY-kinases) and their cognate phosphatases. The ability to regulate capsule biosynthesis has been shown to be vital for pathogenicity, because different stages of infection require a shift in capsule thickness, making the phosphoregulatory proteins suitable as drug targets. Here, we review the role of regulatory proteins focusing on Streptococcus pneumoniae, Staphylococcus aureus, and Escherichia coli and discuss their suitability as targets in structure-based drug design.
Keywords: Antibiotic resistance, bacterial pathogens, capsule, drug discovery, protein tyrosine kinase, protein tyrosine phosphatase, Wzy, Bacterial Capsule, capsular polysaccharide (CPS), bacterial-tyrosine kinases (BY-kinases).
Current Drug Targets
Title:Wzy-Dependent Bacterial Capsules as Potential Drug Targets
Volume: 13 Issue: 11
Author(s): Daniel J. Ericsson, Alistair Standish, Bostjan Kobe and Renato Morona
Affiliation:
Keywords: Antibiotic resistance, bacterial pathogens, capsule, drug discovery, protein tyrosine kinase, protein tyrosine phosphatase, Wzy, Bacterial Capsule, capsular polysaccharide (CPS), bacterial-tyrosine kinases (BY-kinases).
Abstract: The bacterial capsule is a recognized virulence factor in pathogenic bacteria. It likely works as an antiphagocytic barrier by minimizing complement deposition on the bacterial surface. With the continual rise of bacterial pathogens resistant to multiple antibiotics, there is an increasing need for novel drugs. In the Wzy-dependent pathway, the biosynthesis of capsular polysaccharide (CPS) is regulated by a phosphoregulatory system, whose main components consist of bacterial-tyrosine kinases (BY-kinases) and their cognate phosphatases. The ability to regulate capsule biosynthesis has been shown to be vital for pathogenicity, because different stages of infection require a shift in capsule thickness, making the phosphoregulatory proteins suitable as drug targets. Here, we review the role of regulatory proteins focusing on Streptococcus pneumoniae, Staphylococcus aureus, and Escherichia coli and discuss their suitability as targets in structure-based drug design.
Export Options
About this article
Cite this article as:
J. Ericsson Daniel, Standish Alistair, Kobe Bostjan and Morona Renato, Wzy-Dependent Bacterial Capsules as Potential Drug Targets, Current Drug Targets 2012; 13 (11) . https://dx.doi.org/10.2174/138945012803530279
DOI https://dx.doi.org/10.2174/138945012803530279 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diagnosis and Treatment of Pulmonary Fungal Infections in Critically Ill Patients
Current Respiratory Medicine Reviews Design and Optimization of Itraconazole Loaded SLN for Intranasal Administration Using Central Composite Design
Nanoscience & Nanotechnology-Asia Brain Perfusion In Sepsis
Current Vascular Pharmacology Severe Hemorrhagic Cystitis Associated with BK Polyoma Virus Infection Following Lung Transplantation
Current Respiratory Medicine Reviews The Epidemiological and Pangenome Landscape of <i>Staphylococcus aureus</i> and Identification of Conserved Novel Candidate Vaccine Antigens
Current Proteomics Immunotherapy in Invasive Fungal Infection - Focus on Invasive Aspergillosis
Current Pharmaceutical Design Cisternal Sustained Release Dihydropyridines for Subarachnoid Hemorrhage
Current Neurovascular Research Investigating <i>Bacopa monnieri L.</i> Therapeutic Potential for the Treatment of Neurological Diseases
Current Pharmaceutical Design MicroRNAs and Stem Cells to the Rescue
Current Neurovascular Research Association Between Seizures and Diabetes Mellitus: A Comprehensive Review of Literature
Current Diabetes Reviews Viruses and Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Emerging Treatment Strategies
Current Pharmaceutical Biotechnology Biopharmaceutics, Pharmacokinetics and Pharmacodynamics of Antituberculosis Drugs
Current Medicinal Chemistry Burkholderia mallei and Burkholderia pseudomallei: The Causative Micro-organisms of Glanders and Melioidosis
Recent Patents on Anti-Infective Drug Discovery Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews Delivery of Neurotherapeutics Across the Blood Brain Barrier in Stroke
Current Pharmaceutical Design Aspartic Proteases of Human Pathogenic Fungi are Prospective Targets for the Generation of Novel and Effective Antifungal Inhibitors
Current Enzyme Inhibition Intrathecal Rituximab Therapy in Multiple Sclerosis: Review of Evidence Supporting the Need for Future Trials
Current Drug Targets Aβ Oligomers Induce Glutamate Release from Hippocampal Neurons
Current Alzheimer Research Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design